Shareholding disclosure

Newron Pharmaceuticals SpA

Declared position

15.14%

Threshold

Crossed downwards

Timeline

Published

21.10.2021

Transaction

18.10.2021

Voting rights breakdown

Voting rights acquired0%

Voting rights sold15.14%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TALAJ00037

Beneficial owner

Newron Pharmaceuticals SpA

Declared address

Newron Pharmaceuticals SpA, 20091 Bresso (MI)

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Newron Pharmaceuticals SpA

Newron Pharmaceuticals S.p.A.21.10.2021TALAJ00037

Disclosure summary

Newron Pharmaceuticals SpA disclosed a holding in Newron Pharmaceuticals S.p.A. on the disposal side, published by SIX Exchange Regulation on 21.10.2021, at 15.14% of voting rights. Notice category: Single shareholder.

Disclosed position

15.14%

Voting rights sold

Voting rights acquired0%

Voting rights sold15.14%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Newron Pharmaceuticals SpA disclosed a holding in Newron Pharmaceuticals S.p.A., published on 21.10.2021.

Publication date21.10.2021

Transaction date18.10.2021

Issuing companyNewron Pharmaceuticals S.p.A.

Beneficial ownerNewron Pharmaceuticals SpA

Declared addressNewron Pharmaceuticals SpA, 20091 Bresso (MI)

CategorySingle shareholder

Voting rights acquired0%

Voting rights sold15.14%

Below threshold0%

ExchangeXSWX

Notification IDTALAJ00037

Source: SIX Exchange Regulation · Publication date: 21.10.2021

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open